CG-400549, formerly known as CG-0549, is an enoyl-(acyl-carrier protein) reductase fabl inhibitor potentially for the treatment of compcolicated acute. CG400549 had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin. Among 203 strains of Staphylococcus aureus, the MICs of CG400549 were 0.06 to 1.0 microg/ml, with MIC(50) and MIC(90) values of 0.25 microg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 microg/ml). References: Kim BY, Sohn YT. Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation. Arch Pharm Res. 2011 May;34(5):775-9. doi: 10.1007/s12272-011-0511-7. Epub 2011 Jun 9. PubMed PMID: 21656363.

纯度：≥98%

CAS：934628-27-0